Director Janet Brutschea Haugen Receives Quarterly Phantom Stock Award in West Pharmaceutical Services ($WST)

Executive Summary

On October 2, 2026, West Pharmaceutical Services, Inc. ($WST) reported an acquisition of phantom stock units by Director Janet Brutschea Haugen under the company's Deferred Compensation Plan for Outside Directors. The transaction occurred on September 30, 2026, comprising 44 phantom stock units at a reference price of $370.76 per share, representing an aggregate value of $16,313.44.

Transaction Breakdown

• Security: Phantom Stock Unit (settled in common stock upon termination of service as director)
• Transaction Code: 'A' (Grant, award, or other acquisition under Rule 16b-3(d))
• Quantity: 44 units
• Price: $370.76
• Gross Value: $16,313.44
• Post-Transaction Holdings: 350.87 phantom stock units, in addition to 2,114.18 directly owned shares of common stock (which includes 791 unvested restricted stock units and dividend equivalents).

Market & Governance Context

This transaction represents standard, recurring director compensation credited in the form of deferred phantom equity units at the close of the third quarter. Because it constitutes scheduled non-employee director compensation rather than an open-market purchase or discretionary portfolio shift, it carries low informational significance regarding near-term sentiment or fundamental operational changes.